Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04535271 · ClinicalTrials.gov registry record · Phase 2
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
A Phase 2 study of Leiomyosarcoma, sponsored by Sarcoma Oncology Research Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT04535271 is a Phase 2 study of Leiomyosarcoma that is actively recruiting participants, run by Sarcoma Oncology Research Center. The registered enrollment target is 80 participants, below the 117-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04535271, a Phase 2 study of Leiomyosarcoma, is actively recruiting participants, sponsored by Sarcoma Oncology Research Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
Conditions Studied
Interventions
- DRUG Trabectedin
Study Locations (1)
California
- Sant P Chawla - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-09-09 |
| Est. Completion | 2029-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04535271
The ClinicalTrials.gov registry entry for NCT04535271 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 117-participant average among 16 other Leiomyosarcoma trials with a reported enrollment target (32% lower). The listed sponsor is Sarcoma Oncology Research Center, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Leiomyosarcoma appearing as the primary indexed condition, and to 1 intervention - of which Trabectedin is the first listed.
NCT04535271 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04535271 about?
NCT04535271 is a clinical study titled "Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma". This is an open label phase 2 study using metronomic doses of trabectedin, gemcitabine and dacarbazine given intravenously.
What is the current status of trial NCT04535271?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2021-09-09. Estimated completion is 2029-03-30.
What conditions does trial NCT04535271 study?
This clinical trial studies the following conditions: Leiomyosarcoma.
What interventions are being tested in trial NCT04535271?
The interventions under investigation include: Trabectedin (DRUG).
Who is sponsoring clinical trial NCT04535271?
This trial is sponsored by Sarcoma Oncology Research Center, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04535271 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Leiomyosarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
RECRUITING · Phase 2
-
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
ACTIVE NOT RECRUITING · Phase 2
-
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Nivolumab in Selected Uterine Cancer Patients
COMPLETED · Phase 2
-
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
COMPLETED · Phase 2
-
Bevacizumab and Radiation Therapy for Sarcomas
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.